Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Biologic Trials

Grand Rapids, Michigan

Cancer biologic therapy trials in Grand Rapids, MI

36 cancer biologic therapy studies are recruiting participants at sites in Grand Rapids as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.

Call (888) 343-5902
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Grand Rapids at a glance

  • 36 studies are recruiting at a site in Grand Rapids.
  • By phase: Phase 1 (8), Phase 1/2 (1), Phase 2 (8), Phase 2/3 (1), Phase 3 (18).
  • By sponsor: government (13), industry (13), university, hospital or other (10).
  • By research area: Lymphoma (13), Breast Cancer (9), Lung Cancer (7), Melanoma (4), Pancreatic Cancer (2), Prostate Cancer (1).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Grand Rapids

Basic details from each study's public record (the 30 most recently updated of 36). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
    Registry record
    NCT05564377 · updated
  2. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Cancer & Hematology Centers of Western Michigan ( Site 0026)
    Registry record
    NCT06841354 · updated
  3. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
    Registry record
    NCT06058377 · updated
  4. Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer

    • Phase 1
    • Ages 18 and older
    • Female participants
    Sponsor
    Immunomic Therapeutics, Inc.
    Study site
    START Midwest
    Registry record
    NCT07652242 · updated
  5. A Study of MGC026 in Participants With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    MacroGenics
    Study site
    START Midwest
    Registry record
    NCT06242470 · updated
  6. A Study of PHST001 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pheast Therapeutics
    Study site
    START Center for Cancer Research - Midwest
    Registry record
    NCT06840886 · updated
  7. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
    Registry record
    NCT06876714 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Grand Rapids, MI on ClinicalTrials.gov.

Lung cancer studies recruiting in Grand Rapids

  1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
    Registry record
    NCT06498635 · updated
  2. Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
    Registry record
    NCT07388524 · updated
  3. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
    Registry record
    NCT04267848 · updated
  4. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
    Registry record
    NCT06096844 · updated
  5. DBC-664 in Adult Patients With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Duboce Biopharmaceuticals, Inc.
    Study site
    START Midwest
    Registry record
    NCT07705035 · updated
  6. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital
    Registry record
    NCT06116682 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Grand Rapids, MI on ClinicalTrials.gov.

Prostate cancer studies recruiting in Grand Rapids

  1. JUR-003 in Adult Patients With Metastatic Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Juri Biosciences, Inc.
    Study site
    START Midwest
    Registry record
    NCT07824349 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Grand Rapids, MI on ClinicalTrials.gov.

Melanoma studies recruiting in Grand Rapids

  1. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
    Registry record
    NCT05136196 · updated
  2. A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    ModernaTX, Inc.
    Study site
    START Midwest
    Registry record
    NCT06880549 · updated
  3. A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Helen DeVos Children's Hospital at Spectrum Health · Spectrum Health at Butterworth Campus · Trinity Health Grand Rapids Hospital
    Registry record
    NCT04511013 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Grand Rapids, MI on ClinicalTrials.gov.

Lymphoma studies recruiting in Grand Rapids

  1. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
    Registry record
    NCT06317662 · updated
  2. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
    Registry record
    NCT06337318 · updated
  3. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Corewell Health ( Site 0130)
    Registry record
    NCT06717347 · updated
  4. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
    Registry record
    NCT04269902 · updated
  5. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
    Registry record
    NCT04546399 · updated
  6. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital · Trinity Health Grand Rapids Hospital
    Registry record
    NCT05675410 · updated
  7. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 18 to 39
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
    Registry record
    NCT03150693 · updated
  8. A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Corewell Health ( Site 0162)
    Registry record
    NCT05139017 · updated
  9. Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

    • Phase 1/2
    • From 6 months, up to 25 years
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Corewell Health ( Site 1001)
    Registry record
    NCT06395103 · updated
  10. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
    Registry record
    NCT06124157 · updated
  11. Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital
    Registry record
    NCT05633615 · updated
  12. A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Umoja Biopharma
    Study site
    START Midwest
    Registry record
    NCT06528301 · updated
  13. Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

    • Phase 3
    • From 365 days, up to 25 years
    • All sexes
    Sponsor
    Children's Oncology Group
    Study site
    Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
    Registry record
    NCT03959085 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Grand Rapids, MI on ClinicalTrials.gov.

Ask about studies near Grand Rapids

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Michigan

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-5902

or send a short form

How should we reach you?

Call